Browse > Article
http://dx.doi.org/10.3345/kjp.2010.53.4.510

Clinical significance of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 and 2 in Kawasaki disease  

Yun, Ki-Wook (Department of Pediatrics, College of Medicine, Chung-Ang University)
Yun, Sin-Weon (Department of Pediatrics, College of Medicine, Chung-Ang University)
Lee, Jung-Ju (Department of Pediatrics, College of Medicine, Chung-Ang University)
Chae, Soo-Ahn (Department of Pediatrics, College of Medicine, Chung-Ang University)
Lim, In-Seok (Department of Pediatrics, College of Medicine, Chung-Ang University)
Choi, Eung-Sang (Department of Pediatrics, College of Medicine, Chung-Ang University)
Yoo, Byoung-Hoon (Department of Pediatrics, College of Medicine, Chung-Ang University)
Lee, Mi-Kyung (Department of Laboratory Medicine, College of Medicine, Chung-Ang University)
Publication Information
Clinical and Experimental Pediatrics / v.53, no.4, 2010 , pp. 510-518 More about this Journal
Abstract
Purpose : Kawasaki disease (KD) is a systemic vasculitis, a leading cause of pediatric acquired heart disease. Histopathological findings of coronary artery lesion (CAL) in KD indicate destruction of the coronary artery wall with diffuse vasculitis. Matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs) might play central roles in this process. Special attention to MMP-9 has recently been emerging. This study was performed to investigate the clinical significance of MMP-9 and its inhibitors, TIMP-1 and TIMP-2, in KD. Methods : We compared 47 KD patients with 14 febrile controls. Serum MMP-9 and TIMP-1, TIMP-2 were measured by ELISA and compared according to clinical stages and coronary involvement. Results : In acute stage, MMP-9 and TIMP-1 were significantly higher, whereas TIMP-2 was lower, in KD than those in febrile controls ($P$<0.05). The elevated MMP-9 levels in acute phase significantly decreased during the subacute and convalescent phases ($P$<0.05). During acute phase, the MMP-9, TIMP-1, and MMP-9/TIMP-2 levels in the CAL group were lower than those in the non-CAL group, but they increased significantly in the subacute phase ($P$<0.05). MMP-9 has a positive correlation with TIMP-1 in the acute and subacute phases, and negative correlation with TIMP-2 in the subacute and convalescent phases ($P$<0.05). Conclusion : These results suggest that MMP-9, TIMP-1, and the imbalance in MMP-9 and TIMP-2 might play important roles on the pathophysiology of KD and especially on the development of CAL. However, further larger studies are needed.
Keywords
Kawasaki disease; Matrix metalloproteinase; Tissue inhibitor of metalloproteinases; Coronary vessels;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Wood LE, Tulloh RM. Kawasaki disease in children. Heart 2009;95;787-92.   DOI
2 Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thomson RW. Elevated plasma levels of matrix metalloproteinase- 9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000;11:1345-52.   DOI   ScienceOn
3 Matsuyama T. Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis. Pediatr Int 1999;41:239-45.   DOI   ScienceOn
4 Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
5 Lau AC, Duong TT, Ito S, Yeung RS. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum 2008;58:854-63.   DOI   ScienceOn
6 Lau AC, Duong TT, Ito S, Yeung RS. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009;60:2131-41.   DOI   ScienceOn
7 Peng Q, Zhou TF, Chen CH, Jua YM, Liu HM, Hong H, et al. Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease. Zhonghua Er Ke Za Zhi 2005;43:676-80.
8 Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr Int 2002;44:1-4.   DOI   ScienceOn
9 Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008;40:35-42.   DOI   ScienceOn
10 Yang JH, Park MH, Shim JY, Jung HL, Park MS, Keum DH. Increased matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in the cerebrospinal fluid from children with aseptic meningitis. J Korean Pediatr Soc 2003;46:548-53.
11 Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004;24:1479-84.   DOI   ScienceOn
12 Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: Clinical observations of 50 cases (in Japanese). Arerugi 1967;16:178-222.
13 Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97.   DOI   ScienceOn
14 American Heart Association, Inc. Adapted in part from the Japan Kawasaki Disease Research Committee. Circulation 2001;103:335-6.   DOI   ScienceOn
15 Rowley AH, Gonzalez-Crussi F, Gidding SS, Duffy CE, Shulman ST. Incomplete Kawasaki disease with coronary artery involvement. J Pediatr 1987;110:409-13.   DOI
16 Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr opin Chem Biol 1998;2:466-71.   DOI   ScienceOn
17 Park YW. Epidemiology of Kawasaki disease in Korea. Korean J Pediatr 2008; 51:452-6.   DOI   ScienceOn
18 Herron GS, Unemori E, Wong M, Rapp JH, Hibbs MH, Stoney RJ. Connective tissue proteinases and inhibitors in abdominal aortic aneurysms involvement of the vasa vasorum in the pathogenesis of aortic aneurysms. Arterioscler Thromb 1991;11:1667-77.   DOI
19 Lau AC, Duong TT, Ito S, Wilson GJ, Yeung RS. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol 2009;157:300-9.   DOI   ScienceOn
20 Li YY, Feldman RM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-34.   DOI   ScienceOn
21 Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase- 9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001;125:340-4.   DOI   ScienceOn
22 Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-94.   DOI   ScienceOn
23 Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001;104;860-3.   DOI   ScienceOn
24 Zhang Y, McCluskey K, Fujii K, Wahl LM. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte- macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 1998;161:3071-6.
25 Lee YH, Kim TY, Hong YM. Metalloproteinase-3 genotype as a predictor of cardiovascular risk in hypertensive adolescents. Korean Circ J 2009;39:328-4.   DOI   ScienceOn
26 Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003;23:576-81.   DOI   ScienceOn
27 Pugin J, Widmer MC, Kossodo S, liang CM, Preas HL Il, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999;20:458-64.   DOI   ScienceOn
28 Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003;112:495-501.   DOI   ScienceOn
29 Cho EY, Eun BW, Kim NH, Lee JN, Choi EH, Lee HJ, et al. Association between Kawasaki disease and acute respiratory viral infections. Korean J Pediatr 2009;52:1241-8.   DOI   ScienceOn
30 Lin J, Davis HB, Dai Q, Chou YM, Craig T, Hinojosa- Laborde C, et al. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res 2008;31:1225-31.   DOI   ScienceOn
31 Cho AR, Hong YM. Matrix metalloproteinases, tissue inhibitors and cytokines in patients with Kawasaki disease. Korean J Pediatr 2004;47:656-64.
32 Tsuchida S, Yamanaka T, Tsuchida R, Nakamura Y, Yashiro M, Yanagawa H. Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta Pediatr 1996;85:995-7.   DOI   ScienceOn
33 Chua PK, Melish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during acute phase of Kawasaki disease. Clin Dign Lab Immunol 2003;10:308-14.
34 Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertesion. Hypertens Res 2007;30:959-63.   DOI   ScienceOn